Company Overview and News

135
20 Stocks With Renewed Bull Cases After Trump-Kim Summit

2018-06-13 investorplace
The importance of President Donald Trump’s recent meeting with North Korean dictator Kim Jong Un cannot be overstated. For the first time in history, a sitting U.S. President met face-to-face with the hermit nation’s leader. Not only that, the entire world at least temporarily spares itself the prospect of all-out nuclear war.
LMT KWHIF KEP CAT SKM PKX KTOS KT TWTR 8306 6367 7012 MBFJF SHG DKILY SKMD KB HYUO CATR HXSCF KWHIY WF HYUD DKILF KMTUF LPL JPM MUFG RTN HYUP MTU HXSCL

1
SHG / Shinhan Financial Group Co., Ltd. 6-K. FY2018 1Q BUSINESS REPORT (Current Report of Foreign Issuer)

2018-05-15 sec.gov
shg-6k_20180515.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SHG

1
SHG / Shinhan Financial Group Co., Ltd. FORM 20-F

2018-04-30 sec.gov
Form 20-F Table of Contents As filed with the Securities and Exchange Commission on April 30, 2018
SHG

0
SHG / Shinhan Financial Group Co., Ltd. 6-K. SHINHAN FINANCIAL GROUP 2018 1Q OPERATING RESULTS (Current Report of Foreign Issuer)

2018-04-20 sec.gov
shg-6k_20180420.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SHG

0
Korean Banks: Regulatory Risks Vs. Fundamentals

2018-04-20 seekingalpha
Banking shares have been underperforming the KOSPI by 5.9% YTD due to regulatory uncertainties over Korean banks in the wake of a hiring scandal. A 5.7% YTD decline in banking shares in major advanced countries coupled with a recent interest cut also contributed to the weakness in shares. Meanwhile, our strategy team believes that banking shares are oversold, considering: 1) the mitigating risks of the global market; 2) favorable macro conditions underscored by the prospect of interest rate hikes and a stronger KRW in 2H18; and 3) a turnaround of ERR.
SHG HNFGF

0
SHG / Shinhan Financial Group Co., Ltd. 6-K. RESPONSE TO PRESS REPORT (Current Report of Foreign Issuer)

2018-04-11 sec.gov
shg-6k_20180411.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SHG

0
0
SHG / Shinhan Financial Group Co., Ltd. 6-K. FY2017 BUSINESS REPORT (Current Report of Foreign Issuer)

2018-04-02 sec.gov
shg-6k_20180402.htm SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
SHG

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to SHG / Shinhan Financial Group Co., Ltd. on message board site Silicon Investor.

Joshua Gold Resources (JSHG) USHG / Ionatron
USHG: U.S. Home u0026 Garden, Inc. CashGuard
USHG - Anyone know Estimated earnings? SHGE is symbol for SUN HEALTHCARE GROUP
Sun Healthcare [SHG]
CUSIP: 824596100